logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Modernatx, Inc.


USPTO Granted Patents = 246

% Expired Patents = 0.41


Trademarks = 27

Forward Citations = 4,041

Loading Chart...
Loading Chart...

191 inventors (with patents filed for the assignee):

goldMedal Kerry Benenato (58 out of 60 patents)

silverMedal Giuseppe Ciaramella (56 out of 57 patents)

bronzeMedal Stephen G Hoge (53 out of 62 patents)

4.  Vladimir Presnyak (39 out of 42 patents)

5.  Ellalahewage Sathyajith Kumarasinghe (37 out of 38 patents)

6.  Iain McFadyen (31 out of 31 patents)

7.  Sunny Himansu (29 out of 30 patents)

8.  Joshua P Frederick (27 out of 27 patents)

9.  Sayda Mahgoub Elbashir (26 out of 57 patents)

10.  Ailin Bai (22 out of 28 patents)

11.  Stephane Bancel (22 out of 31 patents)

12.  Eric Yi-Chun Huang (21 out of 21 patents)

13.  Antonin De Fougerolles (21 out of 21 patents)

14.  Tirtha Chakraborty (20 out of 45 patents)

15.  Justin Guild (19 out of 22 patents)


Core Competencies:
Nucleic Acid Vaccines
Lipid Nanoparticles
mRNA Quantification
Therapeutic Agents
RNA Formulations
Intracellular Delivery
Modified Nucleosides
Vaccine Development
Polynucleotides
RNA Polymerase Variants
Therapeutic Administration
Intravenous Therapeutics

246 patents:

1. 12741019 - VARIANT STRAIN-BASED CORONAVIRUS VACCINES (2026-09-22),
2. 12740943 - Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents (2026-09-22),
3. 12691177 - Stabilized formulations (2026-07-28),
4. 12685785 - POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA (2026-07-21),
5. 12644102 - POLYNUCLEOTIDES ENCODING BRANCHED-CHAIN ALPHA-KETOACID DEHYDROGENASE COMPLEX E1-ALPHA, E1-BETA, AND E2 SUBUNITS FOR THE TREATMENT OF MAPLE SYRUP URINE DISEASE (2026-06-02),
6. 12629412 - BETACORONAVIRUS mRNA VACCINES (2026-05-19),
7. 12622960 - VARICELLA ZOSTER VIRUS (VZV) VACCINE (2026-05-12),
8. D1125545 - Syringe cap wrench (2026-05-05),
9. 12595226 - Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents (2026-04-07),
10. 12552738 - Crystal forms of amino lipids (2026-02-17),
11. 12529047 - mRNA quantification methods (2026-01-20),
12. 12521577 - BETACORONAVIRUS RNA VACCINES (2026-01-13),
13. 12508278 - Lipid nanoparticle compositions and methods of formulating the same (2025-12-30),
14. 12502431 - DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS (2025-12-23),
15. 12496561 - VORTEX MIXERS AND ASSOCIATED METHODS, SYSTEMS, AND APPARATUSES THEREOF (2025-12-16),
Modernatx, Inc., based in Cambridge, MA, specializes in the development of nucleic acid vaccines, leveraging advanced technologies in lipid nanoparticles and RNA formulations. The company focuses on innovative therapeutic agents that enhance intracellular delivery and mRNA quantification, contributing significantly to vaccine development. By harnessing modified nucleosides, Modernatx aims to address various health challenges through cutting-edge research in the field of nucleic acid therapeutics.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Modernatx, Inc.
246 Patents

#14 in Cambridge, MA

#104 in Massachusetts

#1,735 in US

#3,527 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Modernatx, Inc.

Forward Citations = 4,041

191 inventors:

goldMedal Kerry Benenato (58 out of 60 patents)

silverMedal Giuseppe Ciaramella (56 out of 57 patents)

bronzeMedal Stephen G Hoge (53 out of 62 patents)

4.  Vladimir Presnyak (39 out of 42 patents)

5.  Ellalahewage Sathyajith Kumarasinghe (37 out of 38 patents)

Please report any incorrect information to [email protected]
Loading…